Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas.
Angiogenesis
Glioma
Neuroinflammation
PET
Perfusion
Proliferation
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
24
12
2020
accepted:
04
04
2021
pubmed:
15
4
2021
medline:
21
10
2021
entrez:
14
4
2021
Statut:
ppublish
Résumé
The objective of this review was to explore the potential clinical application of unconventional non-amino acid PET radiopharmaceuticals in patients with gliomas. A comprehensive search strategy was used based on SCOPUS and PubMed databases using the following string: ("perfusion" OR "angiogenesis" OR "hypoxia" OR "neuroinflammation" OR proliferation OR invasiveness) AND ("brain tumor" OR "glioma") AND ("Positron Emission Tomography" OR PET). From all studies published in English, the most relevant articles were selected for this review, evaluating the mostly used PET radiopharmaceuticals in research centers, beyond amino acid radiotracers and 2-[ At present, the use of non-amino acid PET radiopharmaceuticals specifically designed to assess perfusion, angiogenesis, hypoxia, neuroinflammation, cell proliferation, tumor invasiveness, and other biological features in glioma is still limited. The use of investigational PET radiopharmaceuticals should be further explored considering their promising potential and studies specifically designed to validate these preliminary findings are needed. In the clinical scenario, advancements in the development of new PET radiopharmaceuticals and new imaging technologies (e.g., PET/MR and the application of the artificial intelligence to medical images) might contribute to improve the clinical translation of these novel radiotracers in the assessment of gliomas.
Identifiants
pubmed: 33851243
doi: 10.1007/s00259-021-05352-w
pii: 10.1007/s00259-021-05352-w
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3925-3939Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. https://doi.org/10.3322/caac.21590 .
doi: 10.3322/caac.21590
pubmed: 31912902
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-oncology. 2015;17(Suppl 4):iv1–iv62. https://doi.org/10.1093/neuonc/nov189 .
doi: 10.1093/neuonc/nov189
pubmed: 26511214
pmcid: 4623240
Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:e315–e29. https://doi.org/10.1016/s1470-2045(17)30194-8 .
doi: 10.1016/s1470-2045(17)30194-8
pubmed: 28483413
Wesseling P, Capper D. WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol. 2018;44:139–50. https://doi.org/10.1111/nan.12432 .
doi: 10.1111/nan.12432
pubmed: 28815663
Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-oncology. 2016;18:1199–208. https://doi.org/10.1093/neuonc/now058 .
doi: 10.1093/neuonc/now058
pubmed: 27106405
pmcid: 4999003
Zikou A, Sioka C, Alexiou GA, Fotopoulos A, Voulgaris S, Argyropoulou MI. Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas. Contrast Media Mol Imaging. 2018;2018:6828396. https://doi.org/10.1155/2018/6828396 .
doi: 10.1155/2018/6828396
pubmed: 30627060
pmcid: 6305027
Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540–57. https://doi.org/10.1007/s00259-018-4207-9 .
doi: 10.1007/s00259-018-4207-9
pubmed: 30519867
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72. https://doi.org/10.1200/jco.2009.26.3541 .
doi: 10.1200/jco.2009.26.3541
pubmed: 20231676
Langen KJ, Galldiks N, Hattingen E, Shah NJ. Advances in neuro-oncology imaging. Nat Rev Neurol. 2017;13:279–89. https://doi.org/10.1038/nrneurol.2017.44 .
doi: 10.1038/nrneurol.2017.44
pubmed: 28387340
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16:e534–e42. https://doi.org/10.1016/s1470-2045(15)00088-1 .
doi: 10.1016/s1470-2045(15)00088-1
pubmed: 26545842
pmcid: 4638131
Quartuccio N, Asselin MC. The validation path of hypoxia PET imaging: a focus on brain tumours. Curr Med Chem. 2017. https://doi.org/10.2174/0929867324666171116123702 .
Riccardo L, Natale Q, Pierpaolo A, Domenico A, Maria G, Rexhep D, et al. 18F-FMISO PET imaging: insights over MRI in patients with glioma. Clin Transl Imaging. 2020;8:3–10. https://doi.org/10.1007/s40336-019-00353-0 .
doi: 10.1007/s40336-019-00353-0
McKinley ET, Ayers GD, Smith RA, Saleh SA, Zhao P, Washington MK, et al. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One. 2013;8:e58938. https://doi.org/10.1371/journal.pone.0058938 .
doi: 10.1371/journal.pone.0058938
pubmed: 23554961
pmcid: 3598948
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. https://doi.org/10.1371/journal.pmed.1000097 .
doi: 10.1371/journal.pmed.1000097
pubmed: 19621072
pmcid: 2707599
Mendichovszky I, Jackson A. Imaging hypoxia in gliomas. Br J Radiol. 2011;84 Spec No 2:S145–58. https://doi.org/10.1259/bjr/82292521 .
Fink JR, Muzi M, Peck M, Krohn KA. Multimodality brain tumor imaging: MR imaging, PET, and PET/MR imaging. J Nucl Med. 2015;56:1554–61. https://doi.org/10.2967/jnumed.113.131516 .
doi: 10.2967/jnumed.113.131516
pubmed: 26294301
Provenzale JM, York G, Moya MG, Parks L, Choma M, Kealey S, et al. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. Am J Roentgenol. 2006;187:1036–42. https://doi.org/10.2214/AJR.04.0676 .
doi: 10.2214/AJR.04.0676
Lüdemann L, Warmuth C, Plotkin M, Förschler A, Gutberlet M, Wust P, et al. Brain tumor perfusion: comparison of dynamic contrast enhanced magnetic resonance imaging using T1, T2, and T2* contrast, pulsed arterial spin labeling, and H215O positron emission tomography. Eur J Radiol. 2009;70:465–74. https://doi.org/10.1016/j.ejrad.2008.02.012 .
doi: 10.1016/j.ejrad.2008.02.012
pubmed: 18359598
Essig M, Shiroishi MS, Nguyen TB, Saake M, Provenzale JM, Enterline D, et al. Perfusion MRI: the five most frequently asked technical questions. AJR Am J Roentgenol. 2013;200:24–34. https://doi.org/10.2214/ajr.12.9543 .
doi: 10.2214/ajr.12.9543
pubmed: 23255738
pmcid: 3593114
Fan AP, Jahanian H, Holdsworth SJ, Zaharchuk G. Comparison of cerebral blood flow measurement with [15O]-water positron emission tomography and arterial spin labeling magnetic resonance imaging: a systematic review. J Cereb Blood Flow Metab. 2016;36:842–61. https://doi.org/10.1177/0271678X16636393 .
doi: 10.1177/0271678X16636393
pubmed: 26945019
pmcid: 4853843
McKenzie CG, Lenzi GL, Jones T, Moss S. Radioactive oxygen 15O studies in cerebral neoplasms. J R Soc Med. 1978;71:417–25.
doi: 10.1177/014107687807100606
pubmed: 702481
pmcid: 1436465
Nariai T, Senda M, Ishii K, Maehara T, Wakabayashi S, Toyama H, et al. Three-dimensional imaging of cortical structure, function and glioma for tumor resection. J Nucl Med. 1997;38:1563–8.
pubmed: 9379193
Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med. 2004;45:1851–9.
pubmed: 15534054
Xiangsong Z, Changhong L, Weian C, Dong Z. PET imaging of cerebral astrocytoma with 13N-ammonia. J Neuro-Oncol. 2006;78:145–51. https://doi.org/10.1007/s11060-005-9069-x .
doi: 10.1007/s11060-005-9069-x
Xiangsong Z, Xinjian W, Yong Z, Weian C. 13N-NH3: a selective contrast-enhancing tracer for brain tumor. Nucl Med Commun. 2008;29:1052–8. https://doi.org/10.1097/MNM.0b013e328310af34 .
doi: 10.1097/MNM.0b013e328310af34
pubmed: 18987525
Lüdemann L, Warmuth C, Plotkin M, Förschler A, Gutberlet M, Wust P, et al. Brain tumor perfusion: comparison of dynamic contrast enhanced magnetic resonance imaging using T1, T2, and T2* contrast, pulsed arterial spin labeling, and H2(15)O positron emission tomography. Eur J Radiol. 2009;70:465–74. https://doi.org/10.1016/j.ejrad.2008.02.012 .
doi: 10.1016/j.ejrad.2008.02.012
pubmed: 18359598
Shi X, Yi C, Wang X, Zhang B, Chen Z, Tang G, et al. 13N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess. Clin Nucl Med. 2015;40:195–9. https://doi.org/10.1097/RLU.0000000000000649 .
doi: 10.1097/RLU.0000000000000649
pubmed: 25546194
Yi C, Shi X, Zhang X, Luo G, Zhang B, Zhang X. The role of (13)N-ammonia in the differential diagnosis of gliomas and brain inflammatory lesions. Ann Nucl Med. 2019;33:61–7. https://doi.org/10.1007/s12149-018-1308-2 .
doi: 10.1007/s12149-018-1308-2
pubmed: 30350180
He Q, Zhang L, Zhang B, Shi X, Yi C, Zhang X. Diagnostic accuracy of (13)N-ammonia PET, (11)C-methionine PET and (18)F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma. BMC Cancer. 2019;19:332. https://doi.org/10.1186/s12885-019-5560-1 .
doi: 10.1186/s12885-019-5560-1
pubmed: 30961564
pmcid: 6454631
Xiangsong Z, Weian C. Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET. J Neuro-Oncol. 2007;82:305–11. https://doi.org/10.1007/s11060-006-9286-y .
doi: 10.1007/s11060-006-9286-y
Khangembam BC, Sharma P, Karunanithi S, Singhal A, Das CJ, Kumar P, et al. 13N-Ammonia PET/CT for detection of recurrent glioma: a prospective comparison with contrast-enhanced MRI. Nucl Med Commun. 2013;34:1046–54. https://doi.org/10.1097/MNM.0b013e328365bb41 .
doi: 10.1097/MNM.0b013e328365bb41
pubmed: 24025920
Khangembam BC, Karunanithi S, Sharma P, Kc SS, Kumar R, Julka PK, et al. Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT. Neuroradiology. 2014;56:893–902. https://doi.org/10.1007/s00234-014-1389-0 .
doi: 10.1007/s00234-014-1389-0
pubmed: 24989883
Raichle ME, Eichling JO, Straatmann MG, Welch MJ, Larson KB, Ter-Pogossian MM. Blood-brain barrier permeability of 11C-labeled alcohols and 15O-labeled water. Am J Phys. 1976;230:543–52. https://doi.org/10.1152/ajplegacy.1976.230.2.543 .
doi: 10.1152/ajplegacy.1976.230.2.543
Walsh MN, Bergmann SR, Steele RL, Kenzora JL, Ter-Pogossian MM, Sobel BE, et al. Delineation of impaired regional myocardial perfusion by positron emission tomography with H2(15)O. Circulation. 1988;78:612–20. https://doi.org/10.1161/01.cir.78.3.612 .
doi: 10.1161/01.cir.78.3.612
pubmed: 3261646
Bacharach SL, Libutti SK, Carrasquillo JA. Measuring tumor blood flow with H(2)(15)O: practical considerations. Nucl Med Biol. 2000;27:671–6. https://doi.org/10.1016/s0969-8051(00)00136-0 .
doi: 10.1016/s0969-8051(00)00136-0
pubmed: 11091110
Leenders KL. PET: blood flow and oxygen consumption in brain tumors. J Neuro-Oncol. 1994;22:269–73. https://doi.org/10.1007/bf01052932 .
doi: 10.1007/bf01052932
la Fougère C, Suchorska B, Bartenstein P, Kreth F-W, Tonn J-C. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro-oncology. 2011;13:806–19. https://doi.org/10.1093/neuonc/nor054 .
doi: 10.1093/neuonc/nor054
pubmed: 21757446
pmcid: 3145468
Albano D, Giubbini R, Bertagna F. (13)N-NH3 PET/CT in oncological disease. Jpn J Radiol. 2019;37:799–807. https://doi.org/10.1007/s11604-019-00883-7 .
doi: 10.1007/s11604-019-00883-7
pubmed: 31599383
Xiangsong Z, Xingchong S, Chang Y, Xiaoyan W, Zhifeng C. 13N-NH3 versus F-18 FDG in detection of intracranial meningioma: initial report. Clin Nucl Med. 2011;36:1003–6. https://doi.org/10.1097/RLU.0b013e3182291c2a .
doi: 10.1097/RLU.0b013e3182291c2a
pubmed: 21975388
He Q, Shi X, Zhang L, Yi C, Zhang X, Zhang X. De novo glutamine synthesis: importance for the proliferation of glioma cells and potentials for its detection with 13N-ammonia. Mol Imaging. 2016;15:1536012116645440. https://doi.org/10.1177/1536012116645440 .
doi: 10.1177/1536012116645440
pubmed: 27118759
pmcid: 5470141
Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008;49(Suppl 2):113S–28S. https://doi.org/10.2967/jnumed.107.045922 .
doi: 10.2967/jnumed.107.045922
pubmed: 18523069
Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M. Anti-angiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 2018;11:CD008218-CD. https://doi.org/10.1002/14651858.CD008218.pub4 .
doi: 10.1002/14651858.CD008218.pub4
Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro-oncology. 2009;11:861–70. https://doi.org/10.1215/15228517-2009-024 .
doi: 10.1215/15228517-2009-024
pubmed: 19401596
pmcid: 2802406
Li D, Zhao X, Zhang L, Li F, Ji N, Gao Z, et al. (68)Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study. Mol Pharm. 2014;11:3923–9. https://doi.org/10.1021/mp5003224 .
doi: 10.1021/mp5003224
pubmed: 25093246
pmcid: 4224544
Li D, Zhang J, Ji N, Zhao X, Zheng K, Qiao Z, et al. Combined 68Ga-NOTA-PRGD2 and 18F-FDG PET/CT can discriminate uncommon meningioma mimicking high-grade glioma. Clin Nucl Med. 2018;43:648–54. https://doi.org/10.1097/RLU.0000000000002233 .
doi: 10.1097/RLU.0000000000002233
pubmed: 30052597
Minamimoto R, Jamali M, Barkhodari A, Mosci C, Mittra E, Shen B, et al. Biodistribution of the
doi: 10.1007/s00259-015-3096-4
pubmed: 26062933
Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, et al. Glioblastoma multiforme recurrence: an exploratory study of (18)F FPPRGD2 PET/CT. Radiology. 2015;277:497–506. https://doi.org/10.1148/radiol.2015141550 .
doi: 10.1148/radiol.2015141550
pubmed: 25965900
Zhang H, Liu N, Gao S, Hu X, Zhao W, Tao R, et al. Can an
doi: 10.2967/jnumed.115.165514
pubmed: 26514171
Sun J, Cai L, Zhang K, Zhang A, Pu P, Yang W, et al. A pilot study on EGFR-targeted molecular imaging of PET/CT with 11C-PD153035 in human gliomas. Clin Nucl Med. 2014;39:e20–e6. https://doi.org/10.1097/RLU.0b013e3182a23b73 .
doi: 10.1097/RLU.0b013e3182a23b73
pubmed: 24335566
Wang Z, Zhang M, Wang L, Wang S, Kang F, Li G, et al. Prospective study of (68)Ga-NOTA-NFB: radiation dosimetry in healthy volunteers and first application in Glioma patients. Theranostics. 2015;5:882–9. https://doi.org/10.7150/thno.12303 .
doi: 10.7150/thno.12303
pubmed: 26000059
pmcid: 4440444
Lapa C, Lückerath K, Kleinlein I, Monoranu CM, Linsenmann T, Kessler AF, et al. (68)Ga-Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in Glioblastoma. Theranostics. 2016;6:428–34. https://doi.org/10.7150/thno.13986 .
doi: 10.7150/thno.13986
pubmed: 26909116
pmcid: 4737728
Jansen MH, Veldhuijzen van Zanten SEM, van Vuurden DG, Huisman MC, Vugts DJ, Hoekstra OS, et al. Molecular drug imaging: (89)Zr-bevacizumab PET in children with diffuse intrinsic pontine glioma. J Nucl Med. 2017;58:711–6. https://doi.org/10.2967/jnumed.116.180216 .
doi: 10.2967/jnumed.116.180216
pubmed: 27765855
Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med. 2006;47:763–9.
pubmed: 16644745
Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester H-J, et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333–41.
pubmed: 16085591
Oxboel J, Brandt-Larsen M, Schjoeth-Eskesen C, Myschetzky R, El-Ali HH, Madsen J, et al. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors. Nucl Med Biol. 2014;41:259–67. https://doi.org/10.1016/j.nucmedbio.2013.12.003 .
doi: 10.1016/j.nucmedbio.2013.12.003
pubmed: 24417983
Isal S, Pierson J, Imbert L, Clement A, Collet C, Pinel S, et al. PET imaging of (68)Ga-NODAGA-RGD, as compared with (18)F-fluorodeoxyglucose, in experimental rodent models of engrafted glioblastoma. EJNMMI Res. 2018;8:51. https://doi.org/10.1186/s13550-018-0405-5 .
doi: 10.1186/s13550-018-0405-5
pubmed: 29904818
pmcid: 6003898
Provost C, Prignon A, Rozenblum-Beddok L, Bruyer Q, Dumont S, Merabtene F, et al. Comparison and evaluation of two RGD peptides labelled with (68)Ga or (18)F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma. Oncotarget. 2018;9:19307–16. https://doi.org/10.18632/oncotarget.25028 .
doi: 10.18632/oncotarget.25028
pubmed: 29721204
pmcid: 5922398
Loft MD, Sun Y, Liu C, Christensen C, Huang D, Kjaer A, et al. Improved positron emission tomography imaging of glioblastoma cancer using novel (68)Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR). Amino Acids. 2017;49:1089–100. https://doi.org/10.1007/s00726-017-2407-4 .
doi: 10.1007/s00726-017-2407-4
pubmed: 28316028
Cai W, Chen K, Mohamedali KA, Cao Q, Gambhir SS, Rosenblum MG, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med. 2006;47:2048–56.
pubmed: 17138749
Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med. 2007;48:445–54.
pubmed: 17332623
Chen K, Cai W, Li Z-B, Wang H, Chen X. Quantitative PET imaging of VEGF receptor expression. Mol Imaging Biol. 2009;11:15–22. https://doi.org/10.1007/s11307-008-0172-1 .
doi: 10.1007/s11307-008-0172-1
pubmed: 18784964
Lesniak WG, Chu C, Jablonska A, Du Y, Pomper MG, Walczak P, et al. A distinct advantage to intraarterial delivery of (89)Zr-bevacizumab in PET imaging of mice with and without osmotic opening of the blood-brain barrier. J Nucl Med. 2019;60:617–22. https://doi.org/10.2967/jnumed.118.218792 .
doi: 10.2967/jnumed.118.218792
pubmed: 30315146
pmcid: 6495238
Roncaroli F, Su Z, Herholz K, Gerhard A, Turkheimer FE. TSPO expression in brain tumours: is TSPO a target for brain tumour imaging? Clin Transl Imaging. 2016;4:145–56. https://doi.org/10.1007/s40336-016-0168-9 .
doi: 10.1007/s40336-016-0168-9
pubmed: 27077069
pmcid: 4820497
Cistaro A, Caobelli F, Quartuccio N, Fania P, Pagani M. Uncommon 18F-FDG-PET/CT findings in patients affected by limbic encephalitis: hyper-hypometabolic pattern with double antibody positivity and migrating foci of hypermetabolism. Clin Imaging. 2015;39:329–33. https://doi.org/10.1016/j.clinimag.2014.09.004 .
doi: 10.1016/j.clinimag.2014.09.004
pubmed: 25487436
Dupont A-C, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Tronel C, Arlicot N. Translocator protein-18 kDa (TSPO) positron emission tomography (PET) imaging and its clinical impact in neurodegenerative diseases. Int J Mol Sci. 2017;18:785. https://doi.org/10.3390/ijms18040785 .
doi: 10.3390/ijms18040785
pmcid: 5412369
Cistaro A, Cuccurullo V, Quartuccio N, Pagani M, Valentini MC, Mansi L. Role of PET and SPECT in the study of amyotrophic lateral sclerosis. Biomed Res Int. 2014;2014:237437. https://doi.org/10.1155/2014/237437 .
doi: 10.1155/2014/237437
pubmed: 24818133
pmcid: 4004117
Quartuccio N, Van Weehaeghe D, Cistaro A, Jonsson C, Van Laere K, Pagani M. Positron emission tomography neuroimaging in amyotrophic lateral sclerosis: what is new? Q J Nucl Med. 2014;58:344–54.
Janczar K, Su Z, Raccagni I, Anfosso A, Kelly C, Durrenberger PF, et al. The 18-kDa mitochondrial translocator protein in gliomas: from the bench to bedside. Biochem Soc Trans. 2015;43:579–85. https://doi.org/10.1042/BST20150064 .
doi: 10.1042/BST20150064
pubmed: 26551696
Junck L, Olson JM, Ciliax BJ, Koeppe RA, Watkins GL, Jewett DM, et al. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol. 1989;26:752–8. https://doi.org/10.1002/ana.410260611 .
doi: 10.1002/ana.410260611
pubmed: 2557794
Su Z, Herholz K, Gerhard A, Roncaroli F, Du Plessis D, Jackson A, et al. [
doi: 10.1007/s00259-013-2447-2
pubmed: 23715902
pmcid: 3738844
Buck JR, McKinley ET, Hight MR, Fu A, Tang D, Smith RA, et al. Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline. J Nucl Med. 2011;52:107–14. https://doi.org/10.2967/jnumed.110.081703 .
doi: 10.2967/jnumed.110.081703
pubmed: 21149488
Perrone M, Moon BS, Park HS, Laquintana V, Jung JH, Cutrignelli A, et al. A novel PET imaging probe for the detection and monitoring of translocator protein 18 kDa expression in pathological disorders. Sci Rep. 2016;6:20422. https://doi.org/10.1038/srep20422 .
doi: 10.1038/srep20422
pubmed: 26853260
pmcid: 4745082
Tang D, Hight MR, McKinley ET, Fu A, Buck JR, Smith RA, et al. Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-18F-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide. J Nucl Med. 2012;53:287–94. https://doi.org/10.2967/jnumed.111.095653 .
doi: 10.2967/jnumed.111.095653
pubmed: 22251555
Su Z, Roncaroli F, Durrenberger PF, Coope DJ, Karabatsou K, Hinz R, et al. The 18-kDa mitochondrial translocator protein in human gliomas: an 11C-(R)PK11195 PET imaging and neuropathology study. J Nucl Med. 2015;56:512–7. https://doi.org/10.2967/jnumed.114.151621 .
doi: 10.2967/jnumed.114.151621
pubmed: 25722450
Takaya S, Hashikawa K, Turkheimer FE, Mottram N, Deprez M, Ishizu K, et al. The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas. J Neuro-Oncol. 2007;85:95–103. https://doi.org/10.1007/s11060-007-9396-1 .
doi: 10.1007/s11060-007-9396-1
Choudhary G, Langen K-J, Galldiks N, McConathy J. Investigational PET tracers for high-grade gliomas. Q J Nucl Med. 2018;62:281–94. https://doi.org/10.23736/S1824-4785.18.03105-9 .
doi: 10.23736/S1824-4785.18.03105-9
Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32:1–5. https://doi.org/10.1038/jcbfm.2011.147 .
doi: 10.1038/jcbfm.2011.147
pubmed: 22008728
Owen DRJ, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med. 2011;52:24–32. https://doi.org/10.2967/jnumed.110.079459 .
doi: 10.2967/jnumed.110.079459
pubmed: 21149489
James ML, Fulton RR, Vercoullie J, Henderson DJ, Garreau L, Chalon S, et al. DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med. 2008;49:814–22. https://doi.org/10.2967/jnumed.107.046151 .
doi: 10.2967/jnumed.107.046151
pubmed: 18413395
Blair A, Zmuda F, Malviya G, Tavares AAS, Tamagnan GD, Chalmers AJ, et al. A novel (18)F-labelled high affinity agent for PET imaging of the translocator protein. Chem Sci. 2015;6:4772–7. https://doi.org/10.1039/c5sc01647a .
doi: 10.1039/c5sc01647a
pubmed: 29142713
pmcid: 5667507
Unterrainer M, Fleischmann DF, Vettermann F, Ruf V, Kaiser L, Nelwan D, et al. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative (18)F-GE-180 PET study. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-4491-5 .
Albert NL, Unterrainer M, Fleischmann DF, Lindner S, Vettermann F, Brunegraf A, et al. TSPO PET for glioma imaging using the novel ligand (18)F-GE-180: first results in patients with glioblastoma. Eur J Nucl Med Mol Imaging. 2017;44:2230–8. https://doi.org/10.1007/s00259-017-3799-9 .
doi: 10.1007/s00259-017-3799-9
pubmed: 28821920
Vlodavsky E, Soustiel JF. Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival. J Neuro-Oncol. 2007;81:1–7. https://doi.org/10.1007/s11060-006-9199-9 .
doi: 10.1007/s11060-006-9199-9
Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro-oncology. 2012;14:1473–80. https://doi.org/10.1093/neuonc/nos259 .
doi: 10.1093/neuonc/nos259
pubmed: 23090986
pmcid: 3499015
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20. https://doi.org/10.1007/s00401-016-1545-1 .
doi: 10.1007/s00401-016-1545-1
pubmed: 27157931
Evens N, Vandeputte C, Muccioli GG, Lambert DM, Baekelandt V, Verbruggen AM, et al. Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging. Bioorg Med Chem. 2011;19:4499–505. https://doi.org/10.1016/j.bmc.2011.06.033 .
doi: 10.1016/j.bmc.2011.06.033
pubmed: 21737287
Gagliardi F, Narayanan A, Reni M, Franzin A, Mazza E, Boari N, et al. The role of CXCR4 in highly malignant human gliomas biology: current knowledge and future directions. Glia. 2014;62:1015–23. https://doi.org/10.1002/glia.22669 .
doi: 10.1002/glia.22669
pubmed: 24715652
Hartimath SV, van Waarde A, Dierckx RAJO, de Vries EFJ. Evaluation of N-[(11)C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model. Mol Pharm. 2014;11:3810–7. https://doi.org/10.1021/mp500398r .
doi: 10.1021/mp500398r
pubmed: 25094028
Nadeem Abbas M, Kausar S, Wang F, Zhao Y, Cui H. Advances in targeting the epidermal growth factor receptor pathway by synthetic products and its regulation by epigenetic modulators as a therapy for Glioblastoma. Cells. 2019;8:350. https://doi.org/10.3390/cells8040350 .
doi: 10.3390/cells8040350
pmcid: 6523687
Petrulli JR, Sullivan JM, Zheng M-Q, Bennett DC, Charest J, Huang Y, et al. Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain. Neoplasia. 2013;15:1347–53. https://doi.org/10.1593/neo.131666 .
doi: 10.1593/neo.131666
pubmed: 24403856
pmcid: 3884525
Tang Y, Hu Y, Liu W, Chen L, Zhao Y, Ma H, et al. A radiopharmaceutical [(89)Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo. Nucl Med Biol. 2019;70:23–31. https://doi.org/10.1016/j.nucmedbio.2019.01.007 .
doi: 10.1016/j.nucmedbio.2019.01.007
pubmed: 30826708
Wehrenberg-Klee E, Redjal N, Leece A, Turker NS, Heidari P, Shah K, et al. PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance. Am J Nucl Med Mol Imaging. 2015;5:379–89.
pubmed: 26269775
pmcid: 4529591
Oude Munnink TH, Arjaans MEA, Timmer-Bosscha H, Schröder CP, Hesselink JW, Vedelaar SR, et al. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. J Nucl Med. 2011;52:2001–8. https://doi.org/10.2967/jnumed.111.092809 .
doi: 10.2967/jnumed.111.092809
pubmed: 22072706
den Hollander MW, Bensch F, Glaudemans AWJM, Oude Munnink TH, Enting RH, den Dunnen WFA, et al. TGF-β antibody uptake in recurrent high-grade glioma imaged with 89Zr-fresolimumab PET. J Nucl Med. 2015;56:1310–4. https://doi.org/10.2967/jnumed.115.154401 .
doi: 10.2967/jnumed.115.154401
Röhrich M, Loktev A, Wefers AK, Altmann A, Paech D, Adeberg S, et al. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. Eur J Nucl Med Mol Imaging. 2019;46:2569–80. https://doi.org/10.1007/s00259-019-04444-y .
doi: 10.1007/s00259-019-04444-y
pubmed: 31388723
Röhrich M, Floca R, Loi L, Adeberg S, Windisch P, Giesel FL, et al. FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas. Eur J Radiol. 2020;127:109021. https://doi.org/10.1016/j.ejrad.2020.109021 .
doi: 10.1016/j.ejrad.2020.109021
pubmed: 32344293
Windisch P, Röhrich M, Regnery S, Tonndorf-Martini E, Held T, Lang K, et al. Fibroblast activation protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiother Oncol. 2020;150:159–63. https://doi.org/10.1016/j.radonc.2020.06.040 .
doi: 10.1016/j.radonc.2020.06.040
pubmed: 32598977
Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM, Pieper RO. Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PLoS One. 2013;8:e57610. https://doi.org/10.1371/journal.pone.0057610 .
doi: 10.1371/journal.pone.0057610
pubmed: 23451252
pmcid: 3581484
Beinat C, Alam IS, James ML, Srinivasan A, Gambhir SS. Development of [(18)F]DASA-23 for imaging tumor glycolysis through noninvasive measurement of pyruvate kinase M2. Mol Imaging Biol. 2017;19:665–72. https://doi.org/10.1007/s11307-017-1068-8 .
doi: 10.1007/s11307-017-1068-8
pubmed: 28236227
Beinat C, Patel CB, Haywood T, Shen B, Naya L, Gandhi H, et al. Human biodistribution and radiation dosimetry of [(18)F]DASA-23, a PET probe targeting pyruvate kinase M2. Eur J Nucl Med Mol Imaging. 2020;47:2123–30. https://doi.org/10.1007/s00259-020-04687-0 .
doi: 10.1007/s00259-020-04687-0
pubmed: 31938892
Beinat C. Evaluation of [18F]DASA-23 for non-invasive measurement of aberrantly expressed pyruvate kinase M2 in healthy volunteers and intracranial tumor patients. Mol Imaging Biol. 2019:124.